Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for bone loss prevention post-BMT in beta-thalassemia major
NCT01016093Phase 3Unknown
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2009
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zoledronic acid in osteoporosis, sponsored by Tehran University of Medical Sciences. Status: unknown.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT01016093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01016093.